Register or Sign in to Save this opportunity, or Send an Inquiry.
Rivastigmine TDS
Amarin Technologies S.A. Argentina flag Argentina
Abstract ID:
Transdermal system destined to the treatment of dementia.
Send an Inquiry
RE:
Participants
You

Rivastigmine TDS is indicated for the treatment of dementia of the Alzheimer's type, and dementia associated with Parkinson Disease.

Comparative bioavailability of Rivastigmine TDS vs Exelon® patch has been evaluated in two Phase I clinical studies, obtaining similar PK profiles.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
AMARIN is seeking to license this product for USA, Europe and RoW.
FEATURED
Last Updated Dec 2017
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact